sorafenib has been researched along with sincalide in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (sincalide) | Trials (sincalide) | Recent Studies (post-2010) (sincalide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,015 | 72 | 533 |
| Protein | Taxonomy | sorafenib (IC50) | sincalide (IC50) |
|---|---|---|---|
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 0.0006 | |
| Cholecystokinin receptor type A | Homo sapiens (human) | 0.0006 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.001 | |
| Gastrin/cholecystokinin type B receptor | Mus musculus (house mouse) | 0.0008 | |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM | 1 |
| Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W | 1 |
| Shen, C; Zhang, Z; Zhou, F | 1 |
1 review(s) available for sorafenib and sincalide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for sorafenib and sincalide
| Article | Year |
|---|---|
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Models, Biological; NF-kappa B p50 Subunit; Niacinamide; Organophosphates; Phenanthrenes; Phenylurea Compounds; Prodrugs; Signal Transduction; Sincalide; Sorafenib; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2014 |
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Keloid; Male; Middle Aged; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sincalide; Smad Proteins; Sorafenib; Transforming Growth Factor beta; Young Adult | 2016 |
The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death.
Topics: Animals; Autophagic Cell Death; Beclin-1; Carcinoma, Hepatocellular; Complex Mixtures; Fungi; Humans; Liver Neoplasms; Mammals; Mice; Ribosomal Protein S6 Kinases, 70-kDa; Sincalide; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Trametes | 2022 |